Suboptimal immune recovery and associated factors among people living with HIV/AIDS on second‐line antiretroviral therapy in central China: A retrospective cohort study

The introduction and scale‐up of antiretroviral therapy (ART) have contributed to significantly improved patients with acquired immune deficiency syndrome (AIDS) quality of life and prolongs their survival. This has occurred by suppressing viral replication and recovering the CD4 cell count. However, some patients do not normalize their CD4 cell count, despite suppression of the viral load (VL). Patients with suboptimal immune recovery (SIR), as defined by a VL < 400 copies/ml with a CD4 cell count of<200 cells/μl, after ART initiation, exhibit severe immune dysfunction and have a higher risk of AIDS and non‐AIDS events. In recent years, People living with HIV/AIDS (PLWHA) with first‐line ART failure began to gradually switch to second‐line ART. This study aimed to examine the prevalence and factors affecting SIR among PLWHA who switch to second‐line ART in rural China. A 1‐year retrospective cohort study was conducted among PLWHA who switched to second‐line ART between January 2009 and December 2018. All patients with a VL < 400 copies/ml after 1 year of second‐line ART were included. SIR was defined as a CD4 cell count <200 cells/μl and a VL < 400 copies/ml after 1 year of second‐line ART. The data collected from medical records were analyzed by univariate and multivariate analyses. A total of 5294 PLWHA met the inclusion criteria, 24 died, and 1152 were lost to follow‐up after 1 year of second‐line ART. Among 4118 PLWHA who were followed up, 3039 with a VL < 400 copies/ml had their data analyzed, and the prevalence of SIR was 13.1%. The patients’ mean age at recruitment was 47.6 ± 8.1 years and 45.3% were men. A total of 30.7% of patients were HIV‐positive for >8 years and 88.2% were receiving ART before starting second‐line ART for >3 years. The mean CD4 cell count was 354.8 ± 238.2 cells/μl. A multivariable analysis showed that male sex, single status (unmarried or divorced), and a low CD4 cell count were risk factors for SIR among PLWHA with second‐line ART. The prevalence of SIR among PLWHA who switched to second‐line ART in this retrospective cohort study is lower than that in most other studies. Several factors associated with SIR include male sex, marital status, and CD4 cell count levels in PLWHA.

[1]  Huijun Guo,et al.  The Prevalence of HIV-infected Patients with Virological Suppression but a CD4+ T-cell Count of ≤ 200 Cells/mm3 after Highly Active Antiretroviral Therapy Initiation: A Meta-analysis. , 2021, AIDS reviews.

[2]  Kibriti Mehari Kidane,et al.  Incidence and factors associated with treatment failure among HIV infected adolescent and adult patients on second-line antiretroviral therapy in public hospitals of Northern Ethiopia: Multicenter retrospective study , 2020, PloS one.

[3]  P. Hansasuta,et al.  Characteristics of suboptimal immune response after initiating antiretroviral therapy among people living with HIV with a pre-treatment CD4 T cell count <200 cells/mm3 in Thailand☆ , 2020, Journal of virus eradication.

[4]  Aman Sharma,et al.  Signature genes associated with immunological non-responsiveness to anti-retroviral therapy in HIV-1 subtype-c infection , 2020, PloS one.

[5]  Araya Gebreyesus Wasihun,et al.  Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia , 2018, PloS one.

[6]  Jerome H. Kim,et al.  Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Routy,et al.  Baseline Naive CD4+ T-cell Level Predicting Immune Reconstitution in Treated HIV-infected Late Presenters , 2016, Chinese medical journal.

[8]  A. Justice,et al.  HIV, Aging, and Viral Coinfections: Taking the Long View , 2016, Current HIV/AIDS Reports.

[9]  F. Wit,et al.  Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study , 2016, PloS one.

[10]  A. d’Arminio Monforte,et al.  Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy , 2016, AIDS.

[11]  C. Delaugerre,et al.  P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART , 2016, PLoS pathogens.

[12]  M. Seydi,et al.  Initial suboptimal CD4 reconstitution with antiretroviral therapy despite full viral suppression in a cohort of HIV-infected patients in Senegal. , 2015, Medecine et maladies infectieuses.

[13]  L. Chatenoud,et al.  Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART , 2015, PloS one.

[14]  Addis Asfaw,et al.  CD4 Cell Count Trends after Commencement of Antiretroviral Therapy among HIV-Infected Patients in Tigray, Northern Ethiopia: A Retrospective Cross-Sectional Study , 2015, PloS one.

[15]  M. Fox,et al.  Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort , 2014, Journal of the International AIDS Society.

[16]  Fabiano Oliveira,et al.  Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study , 2011, BMC infectious diseases.

[17]  G. Carcelain,et al.  Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. , 2011, Trends in immunology.

[18]  H. Shang,et al.  Natural history of HIV infection in former plasma donors in rural China , 2010, Frontiers of medicine in China.

[19]  Giulia Marchetti,et al.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Ning Wang,et al.  The development of HIV/AIDS surveillance in China. , 2007, AIDS.

[21]  Dominique L. Cosco,et al.  Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population. , 2007, AIDS research and human retroviruses.

[22]  R. Stone,et al.  Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries: The Antiretroviral Therapy in Low-Income Countries (ART-LINC) Collaboration , 2007, Journal of acquired immune deficiency syndromes.

[23]  Felipe García,et al.  Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count , 2004, Journal of acquired immune deficiency syndromes.

[24]  V. Soriano,et al.  Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides , 2002, AIDS.

[25]  M. Kazatchkine,et al.  Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[26]  K. Squires,et al.  Sex-Based Outcomes of Darunavir–Ritonavir Therapy A Single-Group Trial , 2010 .